Premium Nahrungsergänzungsmittel | artgerecht

Prostate Screening: Early Detection & Examination

Prostate screening involves medical examinations to detect prostate cancer and other prostate conditions at an early stage. Regular check-ups from age 45 can significantly improve treatment outcomes.

Regular tips about health Regular tips about health

Things worth knowing about "Prostate Screening"

Prostate screening involves medical examinations to detect prostate cancer and other prostate conditions at an early stage. Regular check-ups from age 45 can significantly improve treatment outcomes.

What Is Prostate Screening?

Prostate screening refers to medical examinations designed to detect diseases of the prostate gland – particularly prostate cancer (prostate carcinoma) – at an early stage, before any symptoms appear. The prostate is a small gland in the male body located just below the bladder. It plays a role in producing seminal fluid. Prostate cancer is one of the most common cancers in men and can often be treated very effectively when detected early.

Who Should Get Screened?

In Germany, statutory health insurance (GKV) covers an annual prostate screening examination for men from the age of 45. Men at higher risk – for example, those with a family history of prostate cancer – are advised to start screening at age 40. Risk groups include:

Men whose father or brother has been diagnosed with prostate cancer
Men of African-American descent (statistically higher risk)
Men aged 70 and above (generally increased risk due to age)

Screening Methods

Digital Rectal Examination (DRE)

During a digital rectal examination, the doctor manually examines the prostate through the rectum to detect hardening, enlargement, or irregular structures. The examination takes only a few seconds and is covered by statutory health insurance as part of routine cancer screening.

PSA Test (Prostate-Specific Antigen)

The PSA test is a blood test that measures the level of prostate-specific antigen in the bloodstream. PSA is a protein produced by the prostate gland. An elevated PSA level may indicate prostate cancer, but can also be caused by a benign prostatic hyperplasia (BPH) or prostate inflammation (prostatitis). In Germany, the PSA test is generally classified as an individual health service (IGeL) and is not routinely covered by statutory health insurance.

Additional Diagnostic Methods

If abnormalities are found, further investigations may be required:

Transrectal Ultrasound (TRUS): Imaging of the prostate using ultrasound via the rectum
Multiparametric MRI (mpMRI): High-resolution magnetic resonance imaging to assess suspicious areas
Prostate Biopsy: Tissue sampling for microscopic examination to identify cancer cells

What Conditions Can Be Detected?

Prostate screening does not only look for prostate cancer. The following conditions may also be identified:

Benign Prostatic Hyperplasia (BPH): A non-cancerous enlargement of the prostate that can cause urinary problems
Prostatitis: Inflammation of the prostate, which may be acute or chronic
Prostate Carcinoma: Malignant tumor of the prostate

Symptoms to Watch For

Early-stage prostate cancer often causes no symptoms. In more advanced stages, or with other prostate conditions, the following symptoms may appear:

Frequent urge to urinate, especially at night
Weak or interrupted urine stream
Pain or burning during urination
Blood in the urine or semen
Pain in the pelvis, lower back, or hips

If any of these symptoms occur, a doctor should be consulted promptly.

Treatment Options Following Diagnosis

If a significant finding is detected during screening, treatment depends on the type and stage of the condition:

Active Surveillance: For slow-growing early-stage cancer, close monitoring without immediate treatment may be chosen
Radical Prostatectomy: Surgical removal of the prostate gland
Radiation Therapy: External beam radiation or internal radiation (brachytherapy)
Hormone Therapy: Suppression of hormones to slow tumor growth
Medication for BPH: Alpha-blockers or 5-alpha-reductase inhibitors to improve urinary flow

References

Deutsche Krebsgesellschaft – S3 Guideline on Prostate Carcinoma, 2022. Available at: https://www.leitlinienprogramm-onkologie.de
Robert Koch Institute (RKI) – Cancer in Germany, Prostate Cancer, 2021. Available at: https://www.krebsdaten.de
European Association of Urology (EAU) – Guidelines on Prostate Cancer, 2023. Available at: https://uroweb.org

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.